Who are Kalaris Therapeutics, Inc.'s main suppliers?

Kalaris Therapeutics, Inc. (KLRS) key suppliers include: KBI-BIOPHARMA, SHARP-STERILE-MANUFACTURING, STC-BIOLOGICS-INC, UCSD. View the full supplier network at chainsifter.com/chain/KLRS.

Who are Kalaris Therapeutics, Inc.'s major customers?

Kalaris Therapeutics, Inc. (KLRS) key customers include: 4D Molecular Therapeutics, Inc., 4D Molecular Therapeutics, Inc., Eli Lilly and Company, Eli Lilly and Company, Novartis AG and 16 more. View the full customer network at chainsifter.com/chain/KLRS.

What sector is Kalaris Therapeutics, Inc. in?

Kalaris Therapeutics, Inc. (KLRS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Kalaris Therapeutics, Inc. Supplier List (KLRS): 4 Verified Suppliers

4Suppliers

21Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Kalaris Therapeutics, Inc. (KLRS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

27Total relationships

2Distinct source URLs

6High confidence

0.727Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Kalaris Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
KBI-BIOPHARMA	KBI-BIOPHARMA	90%	Additionally, KBI Biopharma, based in North Carolina, is our Contract Development and Manufacturing Organization ("CDMO") for future clinical and commercial supply manufacturing of TH103 drug substance.
SHARP-STERILE-MANUFACTURING	SHARP-STERILE-MANUFACTURING	90%	Our principal contract manufacturers are STC Biologics, Inc. and Sharp Sterile Manufacturing (formerly, Berkshire Sterile Manufacturing Inc.).
STC-BIOLOGICS-INC	STC-BIOLOGICS-INC	90%	Our principal contract manufacturers are STC Biologics, Inc. and Sharp Sterile Manufacturing (formerly, Berkshire Sterile Manufacturing Inc.).
UCSD	UCSD	90%	Under the UCSD Agreement, the Company is required to make annual license maintenance payments of $ 10,000 during the first four anniversaries and $ 15,000 on the fifth and every subsequent anniversar…

Kalaris Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
FDMT	4D Molecular Therapeutics, Inc.	72%	Reciprocal relationship from FDMT graph: Reciprocal relationship from KLRS graph: or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, wi…
FDMT	4D Molecular Therapeutics, Inc.	72%	or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing our…
LLY	Eli Lilly and Company	72%	es or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing …
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from KLRS graph: es or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, …
NVSEF	Novartis AG	72%	or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing our…
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from NVSE…
OCUL	Ocular Therapeutix, Inc.	72%	Reciprocal relationship from OCUL graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from OCUL graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from OCUL g…
OCUL	Ocular Therapeutix, Inc.	72%	or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing our…
OTLK	Outlook Therapeutics, Inc.	72%	Reciprocal relationship from OTLK graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from OTLK graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from OTLK g…
OTLK	Outlook Therapeutics, Inc.	72%	or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing our…
REGN	Regeneron Pharmaceuticals, Inc.	72%	or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing our…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from REGN g…
ADCYTE-LLC	ADCYTE-LLC	62%	debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Heal…
ALLOVIR-AURORA-MERGER-SUB-INC	ALLOVIR-AURORA-MERGER-SUB-INC	62%	efforts and our operations as a public company. We do not currently own or operate any drug development or manufacturing facilities. We rely on Contract Development and Manufacturing Organizations (“…
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	ction with the closing of the Merger on March 18, 2025. 40 Loss on extinguishment and on issuance of convertible promissory notes For the three months ended March 31, 2025, we recognized $0.2 million…
CHEVRON-U-S-A-INC	CHEVRON-U-S-A-INC	62%	rotected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We intend to use registered or unregistered trademarks or trade name…
CORNER-POST-INC	CORNER-POST-INC	62%	rotected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We intend to use registered or unregistered trademarks or trade name…
KALARIS-TX-INC	KALARIS-TX-INC	62%	efforts and our operations as a public company. We do not currently own or operate any drug development or manufacturing facilities. We rely on Contract Development and Manufacturing Organizations (“…
NATURAL-RESOURCES-DEFENSE-COUNCIL-INC	NATURAL-RESOURCES-DEFENSE-COUNCIL-INC	62%	rotected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We intend to use registered or unregistered trademarks or trade name…
USA-LLC	USA-LLC	62%	ommon stock calculated in accordance with an exchange ratio equal to 1:0.2016 (the “Exchange Ratio”). Each award of restricted shares of Legacy Kalaris’ common stock that was unvested and outstanding…
VIRACYTE-LLC	VIRACYTE-LLC	62%	debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Heal…

Kalaris Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
KLRS-DEBT-10529	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.

Kalaris Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Kalaris Therapeutics, Inc..

Kalaris Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
KLRS-OWNER-SAMSARA-BIOCAPITAL-LLC	SAMSARA BIOCAPITAL, LLC	90%	13F overlay lists SAMSARA BIOCAPITAL, LLC as top holder; 58 tracked holders.

Kalaris Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
ALEC	Alector, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
SLGL	Sol-Gel Technologies Ltd.	100.00	2
NVO	Novo Nordisk A/S	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
VEEV	Veeva Systems Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
BYSI	BeyondSpring Inc.	100.00	2

Kalaris Therapeutics, Inc. Supply Chain